| Brian E O'hara, MD | |
|
2500 Fairway St, Dickinson, ND 58601-2639 | |
| (701) 456-4000 | |
| Not Available |
| Full Name | Brian E O'hara |
|---|---|
| Gender | Male |
| Speciality | Pediatric Medicine |
| Experience | 39 Years |
| Location | 2500 Fairway St, Dickinson, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568459113 | NPI | - | NPPES |
| 1452975 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 5807 (North Dakota) | Secondary |
| 207R00000X | Internal Medicine | 5807 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chi Health At Home | Dickinson, ND | Home health agency |
| Chi St Alexius Health Dickinson | Dickinson, ND | Hospital |
| St Benedicts Health Center | Dickinson, ND | Nursing home |
| St Lukes Home | Dickinson, ND | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St. Joseph's Hospital And Health Center | 0547177560 | 76 |
News Archive
Huntington's disease (HD) is characterized by ongoing destruction of specific neurons within the brain. It affects a person's ability to walk, talk, and think - leading to involuntary movement and loss of muscle co-ordination. New research published in BioMed Central's open access journal Molecular Neurodegeneration shows that the RyanR inhibitor Dantrolene is able to reduce the severity of walking and balance problems in a mouse model of HD.
Oncotarget published "JunD accentuates arecoline-induced disruption of tight junctions and promotes epithelial-to-mesenchymal transition by association with NEAT1 lncRNA" which reported that the effects of low and high concentrations of arecoline on the stability of tight junctions and EMT induction were studied.
Women who have had pre-cancerous cells removed remain at higher than average risk of developing cervical cancer in the 20 years following treatment, says research in the British Medical Journal (BMJ).
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.
› Verified 8 days ago
| Entity Name | St. Joseph's Hospital And Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730464108 PECOS PAC ID: 0547177560 Enrollment ID: O20031107000651 |
News Archive
Huntington's disease (HD) is characterized by ongoing destruction of specific neurons within the brain. It affects a person's ability to walk, talk, and think - leading to involuntary movement and loss of muscle co-ordination. New research published in BioMed Central's open access journal Molecular Neurodegeneration shows that the RyanR inhibitor Dantrolene is able to reduce the severity of walking and balance problems in a mouse model of HD.
Oncotarget published "JunD accentuates arecoline-induced disruption of tight junctions and promotes epithelial-to-mesenchymal transition by association with NEAT1 lncRNA" which reported that the effects of low and high concentrations of arecoline on the stability of tight junctions and EMT induction were studied.
Women who have had pre-cancerous cells removed remain at higher than average risk of developing cervical cancer in the 20 years following treatment, says research in the British Medical Journal (BMJ).
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.
› Verified 8 days ago
| Entity Name | Mercy Hospital Of Devils Lake |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790751170 PECOS PAC ID: 9537128681 Enrollment ID: O20041005001141 |
News Archive
Huntington's disease (HD) is characterized by ongoing destruction of specific neurons within the brain. It affects a person's ability to walk, talk, and think - leading to involuntary movement and loss of muscle co-ordination. New research published in BioMed Central's open access journal Molecular Neurodegeneration shows that the RyanR inhibitor Dantrolene is able to reduce the severity of walking and balance problems in a mouse model of HD.
Oncotarget published "JunD accentuates arecoline-induced disruption of tight junctions and promotes epithelial-to-mesenchymal transition by association with NEAT1 lncRNA" which reported that the effects of low and high concentrations of arecoline on the stability of tight junctions and EMT induction were studied.
Women who have had pre-cancerous cells removed remain at higher than average risk of developing cervical cancer in the 20 years following treatment, says research in the British Medical Journal (BMJ).
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian E O'hara, MD 2500 Fairway St, Dickinson, ND 58601-2639 Ph: (701) 456-4000 | Brian E O'hara, MD 2500 Fairway St, Dickinson, ND 58601-2639 Ph: (701) 456-4000 |
News Archive
Huntington's disease (HD) is characterized by ongoing destruction of specific neurons within the brain. It affects a person's ability to walk, talk, and think - leading to involuntary movement and loss of muscle co-ordination. New research published in BioMed Central's open access journal Molecular Neurodegeneration shows that the RyanR inhibitor Dantrolene is able to reduce the severity of walking and balance problems in a mouse model of HD.
Oncotarget published "JunD accentuates arecoline-induced disruption of tight junctions and promotes epithelial-to-mesenchymal transition by association with NEAT1 lncRNA" which reported that the effects of low and high concentrations of arecoline on the stability of tight junctions and EMT induction were studied.
Women who have had pre-cancerous cells removed remain at higher than average risk of developing cervical cancer in the 20 years following treatment, says research in the British Medical Journal (BMJ).
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.
› Verified 8 days ago
Patricia W Anderson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 938 2nd Ave W, Dickinson, ND 58601 Phone: 701-456-6000 Fax: 701-323-5709 | |
Jd Labash, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 1173 3rd Ave W, Ste 12, Dickinson, ND 58601 Phone: 701-483-6777 Fax: 701-483-6776 | |
Bruce W Olin, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 33 9th St W, Dickinson, ND 58601 Phone: 701-483-6017 Fax: 701-483-5018 | |
Mark P Hinrichs, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1532 11th St W, Dickinson, ND 58601 Phone: 701-290-8213 |